Blue Matter Blog
May 15, 2024
What do you think of when you think of psychedelics? Groovy, oscillating patterns and hippies on drugs? What about a ketamine-assisted therapy clinic, or patients who are overcoming their post-traumatic stress disorder (PTSD) and treatment-resistant depression? Increasingly, the clinical benefits of psychedelic medicines are moving to the forefront as further research is conducted and societal …
May 13, 2024
For a biopharma company to be a Best Practice Organization (BPO), it must develop frameworks for measuring the impact of its activities. In this series about what it takes to be a BPO, we have previously examined the importance of having clear vision, mission, and values; capabilities; and ways of working. As valuable as those …
May 10, 2024
Greetings from Atlanta, where the 2024 annual meeting of ISPOR brought the best and brightest in the health economics and outcomes research (HEOR) field together from May 5-8. Blue Matter sent a team to attend and check out the cutting-edge research presented at the conference. While there, our team was treated to a sampling of …
May 3, 2024
Summary This spring, Blue Matter’s London team hosted the third meeting of the UK Biotech Club for C-suite leaders representing 20 London-based biotech companies. The leaders shared their perspectives on the outlook for the UK’s biotech sector and keys to succeed in a competitive industry. Conversation focused on how managing stakeholder relations, particularly with investors …